株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:アルツハイマー病 - 世界の医薬品市場の2023年までの予測と市場分析

PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2023 - Event-Driven Update

発行 GlobalData 商品コード 296448
出版日 ページ情報 英文 407 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:アルツハイマー病 - 世界の医薬品市場の2023年までの予測と市場分析 PharmaPoint: Alzheimer's Disease - Global Drug Forecast and Market Analysis to 2023 - Event-Driven Update
出版日: 2015年05月01日 ページ情報: 英文 407 Pages
概要

アルツハイマー病 (AD) は、記憶喪失、認知障害、機能低下を特徴とする進行性の神経変性疾患です。

当レポートでは、世界のAD治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報 (製品説明、安全性、有効性) 、SWOT分析、売上高予測、影響分析 (動向、促進要因・抑制要因) などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 病期分類システム
  • 症状
  • 予後
  • 生活の質 (QOL)

第4章 疫学

  • 疾患の背景
  • 危険因子と併存疾患
    • ADの家族歴が、ADのリスクを7.5倍に
    • ApoE ε4 対立遺伝子が、ADのリスクを3倍に
    • 心血管疾患の危険因子が、ADのリスクを倍増
    • 65歳以上では、ADの発症件数と有病者数が5歳ごとに倍増
    • 糖尿病は男性のADのリスクを倍増させるが、女性のADのリスクは微増
    • 女性がADを発症するリスクは、男性より1.5倍高い傾向がある
    • 鬱病はADのリスクを3倍に、最も一般的な併存疾患
    • AD患者の70%程度が、不安神経症も患っている
    • 精神病性激越 (興奮) は、AD患者の一般的な併存疾患
  • 世界の動向
    • 米国
    • EU5ヶ国
    • 日本
    • 中国
    • インド
  • 予測手法
    • 利用した情報源
    • 予測の前提条件と手法
    • 利用しなかった情報源
  • 疫学予測
  • 議論

第5章 疾患の管理

  • 診断の概要
  • 治療の概要
  • 臨床診療
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国
  • インド

第6章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド
  • その他の薬剤/薬効分類

第7章 アンメットニーズと機会

  • 疾患修飾性の作用機序を有する薬剤
  • 前駆期または発症前段階の診断
  • 症状コントロールの改善
  • 治療のし易さ

第8章 パイプライン評価

  • 概要
  • 臨床試験マッピング
  • 臨床開発中の有望な薬剤

第9章 現在・将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Actavis
    • Lundbeck
    • エーザイ
    • Pfizer
    • Novartis
    • Roche
    • Eli Lilly
    • Merck & Co. 280
    • AstraZeneca
    • 武田薬品工業

第10章 市場の見通し

  • 世界市場
  • 米国
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • 日本
  • 中国
  • インド

第11章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC010EPIDR

Alzheimer's Disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation either by a home care professional or family member. The rapidly declining status of patients with AD results in a drastic reduction in quality of life (QOL), both for the patients and their caretakers. With rapidly accelerating worldwide prevalence, AD has been identified as a major global health threat by the international medical community. Significant efforts have been made to develop a new treatment for AD, as current pharmacologic management is known to only provide temporary improvement of symptoms. Without therapies that effectively stop or reverse the course of the disease, a large area opportunity exists for the development of an effective pharmacologic approach.

Highlights

Key Questions Answered

  • What are the preferred therapies for each country?
  • The developmental pipeline consists of disease-modifying therapies (DMTs) that aim to prevent the disease in early- and presymptomatic patients. Which of these DMTs will attain high sales revenues during 2013-2023, and in which markets?
  • Will amyloid-based therapies face adoption challenges in the market? What is the projected uptake of new passive immunotherapies and BACE inhibitors over the forecast period?
  • How large an impact will Lundbeck's LuAE-58054 and Forum/Mitsubishi Tanabe's EVP-6124 have on the schizophrenia market? What do key opinion leaders think of these treatment approaches?
  • What are the unique challenges in AD, and how will they affect the growth of the market globally?

Key Findings

  • Guidelines are not closely followed due to the heterogeneity of symptoms.
  • There is a widespread reluctance to seek treatment in the absence of curative therapies.
  • Diagnosis in early stages of the disease remains a challenge and will affect the growth of the market over the 2013-2023 forecast period.
  • Poor consensus over clinical trial endpoints required for approval.
  • Symptoms related to AD require better treatment options.
  • Amyloid beta is the focus of the late-stage pipeline.
  • Disease-modifying therapies such as passive immunotherapies and BACE inhibitors will revitalize the AD market.

Scope

  • Overview of AD and mild cognitive impairment (MCI), including etiology, general symptoms, country-specific compliance/caregiving data and epidemiology.
  • Annualized AD market revenue, annual cost of treatment and usage patterns from 2013 and forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, unmet needs, clinical trial mapping and implications for the AD market.
  • Pipeline analysis: comprehensive data split across AD disease severities for disease-modifying and symptomatic therapies with novel mechanisms of action in AD, including Lilly's solanezumab, Biogen's aducanumab, Roche's gantenerumab and crenezumab (Phase II). Merck & Co.'s M-8931, and Lilly/AstraZeneca's AZD-3293.
  • Analysis of the current and future market competition in the global AD drug market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most competitive pipelines.
  • Develop business strategies by understanding the trends shaping and driving the AD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global AD market from 2013-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Disease Staging Systems
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
    • 4.2.1. A family history of Alzheimer's increases the risk of developing the disease by 7.5 times
    • 4.2.2. The APOE ε4 allele triples the risk for AD
    • 4.2.3. Cardiovascular risk factors in midlife significantly increase the risk of developing AD in later life
    • 4.2.4. The incidence and prevalence of AD double every five years after age 65 years
    • 4.2.5. Diabetes doubles the risk of AD in men, but only marginally affects the risk in women
    • 4.2.6. Women are 1.5 times more likely to develop AD than men
    • 4.2.7. Depression triples the risk for AD, and is the most common comorbidity
    • 4.2.8. Up to 70% of AD patients also suffer from anxiety
    • 4.2.9. Psychosis and agitation are common comorbidities in Alzheimer's patients
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
    • 4.3.4. China
    • 4.3.5. India
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Forecast Assumptions and Methods
    • 4.4.3. Sources Not Used
  • 4.5. Epidemiology Forecast (2013-2023)
    • 4.5.1. Total Prevalent Cases of AD
    • 4.5.2. Age-Specific Total Prevalent Cases of AD
    • 4.5.3. Sex-Specific Total Prevalent Cases of AD
    • 4.5.4. Age-Standardized Total Prevalence of AD
    • 4.5.5. Total Prevalent Cases of AD, by Severity
    • 4.5.6. Total Prevalent Cases of MCI
    • 4.5.7. Age-Specific Total Prevalent Cases of MCI
    • 4.5.8. Sex-Specific Total Prevalent Cases of MCI
    • 4.5.9. Age-Standardized Total Prevalence of MCI
  • 4.6. Discussion
    • 4.6.1. Conclusions Regarding the Epidemiological Trends
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis Overview
    • 5.1.1. Probable AD Dementia
    • 5.1.2. Preclinical AD
    • 5.1.3. MCI
  • 5.2. Treatment Overview
  • 5.3. Clinical Practice
    • 5.3.1. Leading Prescribed Therapies
  • 5.4. US
  • 5.5. France
  • 5.6. Germany
  • 5.7. Italy
  • 5.8. Spain
  • 5.9. UK
  • 5.10. Japan
  • 5.11. China
  • 5.12. India

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands
    • 6.2.1. Aricept (donepezil hydrochloride)
    • 6.2.2. Exelon (rivastigmine, rivastigmine tartrate)
    • 6.2.3. Razadyne (galantamine hydrobromide)
    • 6.2.4. Namenda (memantine hydrochloride)
  • 6.3. Other Drugs/Classes

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. Drugs with Disease-Modifying Mechanisms of Action
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Diagnosis in the Prodromal or Presymptomatic Stages
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Improved Control of Symptoms
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Easier Access to Treatment
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Class
  • 8.3. Promising Drugs in Clinical Development
    • 8.3.1. Biopharmaceutical Products
    • 8.3.2. Small Molecule
    • 8.3.3. Other Drugs in Development

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Actavis
    • 9.3.2. Lundbeck
    • 9.3.3. Eisai
    • 9.3.4. Pfizer
    • 9.3.5. Novartis
    • 9.3.6. Roche
    • 9.3.7. Eli Lilly
    • 9.3.8. Merck & Co.
    • 9.3.9. AstraZeneca
    • 9.3.10. Takeda

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. United States
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. United Kingdom
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers
  • 10.9. China
    • 10.9.1. Forecast
    • 10.9.2. Key Events
    • 10.9.3. Drivers and Barriers
  • 10.10. India
    • 10.10.1. Forecast
    • 10.10.2. Key Events
    • 10.10.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed AD Patients
    • 11.4.2. Percent Drug-Treated Patients
    • 11.4.3. Drugs Included in Each Therapeutic Class
    • 11.4.4. Launch and Patent Expiry Dates
    • 11.4.5. General Pricing Assumptions
    • 11.4.6. Compliance Assumptions
    • 11.4.7. Individual Drug Assumptions
    • 11.4.8. Generic Erosion
    • 11.4.9. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for This Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Three-Stage Classification of AD
  • Table 2: Seven-Stage Reisberg Scale
  • Table 3: Common Symptoms of AD
  • Table 4: Risk Factors and Comorbidities for AD
  • Table 5: DSM-III-R Criteria for the Diagnosis of Dementia
  • Table 6: NINCDS-ADRDA Criteria for the Diagnosis of AD
  • Table 7: 9MM, Epidemiological Sources for AD Total Prevalence Data
  • Table 8: 9MM, Epidemiological Sources for AD Total Prevalence Data, Based on Severity
  • Table 9: 9MM, Epidemiological Sources for MCI Total Prevalence Data
  • Table 10: 9MM, Sources Excluded from the Forecast for the Total Prevalent Cases of AD
  • Table 11: 9MM, Sources Excluded from the Forecast for the Total Prevalent Cases of MCI
  • Table 12: 9MM, Total Prevalent Cases of AD, Ages ≥60 Years, Men and Women, N, 2013-2023
  • Table 13: 9MM, Total Prevalent Cases of AD, by Age, Men and Women, N (Row %), 2013
  • Table 14: 9MM, Total Prevalent Cases of AD, by Sex, Age ≥ 60 Years, N (Row %), 2013
  • Table 15: 9MM, Total Prevalent Cases of AD, by Severity, Men and Women, N (Row %), 2013
  • Table 16: 9MM, Total Prevalent Cases of MCI, Ages ≥60 Years, Men and Women, N, 2013-2023
  • Table 17: 9MM, Total Prevalent Cases of MCI, by Age, Men and Women, N (Row %), 2013
  • Table 18: 9MM, Total Prevalent Cases of MCI, by Sex, Age ≥60 Years, N (Row %), 2013
  • Table 19: Common Used Diagnostic Guidelines for AD
  • Table 20: DSM-IV-TR Diagnostic Criteria for AD
  • Table 21: Summary of NINCDS-ADRDA Diagnostic Criteria for AD
  • Table 22: Proposed NIA-AA Staging Classification for Preclinical AD
  • Table 23: NIA-AA Biomarker Criteria for MCI
  • Table 24: Commonly Used Treatment Guidelines for AD
  • Table 25: Most Prescribed Drugs for AD by Class in the 9MM, 2013
  • Table 26: Most Commonly Prescribed Off-label Drug Classes for AD in the 9MM, 2013
  • Table 27: AD Market Country Profile - US
  • Table 28: AD Market Country Profile - France
  • Table 29: AD Market Country Profile - Germany
  • Table 30: AD Market Country Profile - Italy
  • Table 31: AD Market Country Profile - Spain
  • Table 32: AD Market Country Profile - UK
  • Table 33: AD Market Country Profile - Japan
  • Table 34: AD Market Country Profile - China
  • Table 35: AD Market Country Profile - India
  • Table 36: Leading Therapies in AD, 2013
  • Table 37: Product Profile - Aricept
  • Table 38: Aricept SWOT Analysis, 2013
  • Table 39: Global Sales Forecasts ($m) for Aricept, 2013-2023
  • Table 40: Product Profile - Exelon
  • Table 41: Exelon SWOT Analysis, 2013
  • Table 42: Global Sales Forecasts ($m) for Exelon, 2013-2023
  • Table 43: Product Profile - Razadyne
  • Table 44: Razadyne SWOT Analysis, 2013
  • Table 45: Global Sales Forecasts ($m) for Razadyne, 2013-2023
  • Table 46: Product Profile - Namenda
  • Table 47: Namenda SWOT Analysis, 2013
  • Table 48: Global Sales Forecasts ($m) for Namenda, 2013-2023
  • Table 49: Summary of Other Therapeutic Classes for AD, 2013
  • Table 50: Unmet Need and Opportunity in the AD Market
  • Table 51: Pre-Registration and Phase III Pipeline in AD/MCI, September 2014
  • Table 52: Comparison of Therapeutic Classes in Development for AD
  • Table 53: Product Profile - Solanezumab
  • Table 54: Efficacy Outcomes in EXPEDITION 1, ITT
  • Table 55: Efficacy Outcomes in EXPEDITION 2, ITT
  • Table 56: Outcomes in Mild and Moderate AD Patients in EXPEDITION 1 and 2, ITT
  • Table 57: Summary of Adverse Events in EXPEDITION 1 and EXPEDITION 2
  • Table 58: Solanezumab SWOT Analysis, 2014
  • Table 59: Global Sales Forecasts ($m) for Solanezumab, 2013-2023
  • Table 60: Product Profile - Gantenerumab
  • Table 61: Gantenerumab SWOT Analysis, 2014
  • Table 62: Global Sales Forecasts ($m) for Gantenerumab, 2013-2023
  • Table 63: Product Profile - Crenezumab
  • Table 64: Crenezumab SWOT Analysis, 2014
  • Table 65: Global Sales Forecasts ($m) for Crenezumab, 2013-2023
  • Table 66: Product Profile - Aducanumab
  • Table 67: Mean Change in Composite SUVR from Baseline to Week 26 and Week 54
  • Table 68: Aducanumab SWOT Analysis, 2015
  • Table 69: Global Sales Forecasts ($m) for Aducanumab, 2013-2023
  • Table 70: Product Profile - Flebogamma + Albutein
  • Table 71: Flebogamma + Albutein SWOT Analysis, 2014
  • Table 72: Global Sales Forecasts ($m) for Flebogamma + Albutein, 2013-2023
  • Table 73: Product Profile - Namzaric
  • Table 74: Safety of Namenda in Combination with Aricept
  • Table 75: Namzaric SWOT Analysis, 2014
  • Table 76: Global Sales Forecasts ($m) for Namzaric, 2013-2023
  • Table 77: Product Profile - MK-8931
  • Table 78: MK-8931 SWOT Analysis, 2014
  • Table 79: Global Sales Forecasts ($m) for MK-8931, 2013-2023
  • Table 80: Product Profile - AZD-3293
  • Table 81: AZD-3293 SWOT Analysis, 2014
  • Table 82: Global Sales Forecasts ($m) for AZD-3293, 2013-2023
  • Table 83: Product Profile - TTP-488
  • Table 84: Changes from Baseline in the ADAS-Cog Score
  • Table 85: TTP-488 SWOT Analysis, 2014
  • Table 86: Global Sales Forecasts ($m) for TTP-488, 2013-2023
  • Table 87: Product Profile - TRx-0237
  • Table 88: TRx-0237 SWOT Analysis, 2014
  • Table 89: Global Sales Forecasts ($m) for TRx-0237, 2013-2023
  • Table 90: Product Profile - AB-1010
  • Table 91: Efficacy of AB-1010, as Measured by the ADAS-Cog at Week 24
  • Table 92: Frequency of Adverse Events, AB-1010 Versus Placebo
  • Table 93: AB-1010 SWOT Analysis, 2014
  • Table 94: Global Sales Forecasts ($m) for AB-1010, 2013-2023
  • Table 95: Product Profile - AD-4833
  • Table 96: Common Adverse Events with AD-4833 Versus Placebo
  • Table 97: AD-4833 SWOT Analysis, 2014
  • Table 98: Global Sales Forecasts ($m) for AD-4833, 2013-2023
  • Table 99: Product Profile - EVP-6124
  • Table 100: Treatment-Emergent Adverse Events Observed With EVP-6124 Versus Placebo
  • Table 101: EVP-6124 SWOT Analysis, 2014
  • Table 102: Global Sales Forecasts ($m) for EVP-6124, 2013-2023
  • Table 103: Product Profile - LuAE-58054
  • Table 104: LuAE-58054 SWOT Analysis, 2014
  • Table 105: Global Sales Forecasts ($m) for LuAE-58054, 2013-2023
  • Table 106: Product Profile - ARC-029
  • Table 107: ARC-029 SWOT Analysis, 2014
  • Table 108: Global Sales Forecasts ($m) for ARC-029, 2013-2023
  • Table 109: Drugs in Development, 2014
  • Table 110: Actavis' AD Portfolio Assessment, 2014
  • Table 111: Lundbeck's AD Portfolio Assessment, 2014
  • Table 112: Eisai's AD Portfolio Assessment, 2014
  • Table 113: Pfizer's AD Portfolio Assessment, 2014
  • Table 114: Novartis' AD Portfolio Assessment, 2014
  • Table 115: Roche's AD Portfolio Assessment, 2014
  • Table 116: Eli Lilly's AD Portfolio Assessment, 2014
  • Table 117: Merck's AD Portfolio Assessment, 2014
  • Table 118: AstraZeneca's AD Portfolio Assessment, 2014
  • Table 119: Takeda's AD Portfolio Assessment, 2014
  • Table 120: Global Sales Forecasts ($m) for AD, 2013-2023
  • Table 121: Global AD Market - Drivers and Barriers, 2013-2023
  • Table 122: Sales Forecasts ($m) for AD in the US, 2013-2023
  • Table 123: Key Events Impacting Sales for AD in the US, 2013-2023
  • Table 124: AD Market - Drivers and Barriers in the US, 2013-2023
  • Table 125: Sales Forecasts ($m) for AD in France, 2013-2023
  • Table 126: Key Events Impacting Sales for AD in France, 2013-2023
  • Table 127: AD Market - Drivers and Barriers in France, 2013-2023
  • Table 128: Sales Forecasts ($m) for AD in Germany, 2013-2023
  • Table 129: Key Events Impacting Sales for AD in Germany, 2013-2023
  • Table 130: AD Market - Drivers and Barriers in Germany, 2013-2023
  • Table 131: Sales Forecasts ($m) for AD in Italy, 2013-2023
  • Table 132: Key Events Impacting Sales for AD in Italy, 2013-2023
  • Table 133: AD Market - Drivers and Barriers in Italy, 2013-2023
  • Table 134: Sales Forecasts ($m) for AD in Spain, 2013-2023
  • Table 135: Key Events Impacting Sales for AD in Spain, 2013-2023
  • Table 136: AD Market - Drivers and Barriers in Spain, 2013-2023
  • Table 137: Sales Forecasts ($m) for AD in the UK, 2013-2023
  • Table 138: Key Events Impacting Sales for AD in the UK, 2013-2023
  • Table 139: AD Market - Drivers and Barriers in the UK, 2013-2023
  • Table 140: Sales Forecasts ($m) for AD in Japan, 2013-2023
  • Table 141: Key Events Impacting Sales for AD in Japan, 2013-2023
  • Table 142: AD Market - Drivers and Barriers in Japan, 2013-2023
  • Table 143: Sales Forecasts ($m) for AD in China, 2013-2023
  • Table 144: Key Events Impacting Sales for AD in China, 2013-2023
  • Table 145: AD Market - Drivers and Barriers in China, 2013-2023
  • Table 146: Sales Forecasts ($m) for AD in India, 2013-2023
  • Table 147: Key Events Impacting Sales for AD in India, 2013-2023
  • Table 148: AD Market - Drivers and Barriers in India, 2013-2023
  • Table 149: Key Launch Dates, Marketed and Pipeline AD Products
  • Table 150: Key Patent Expirations, Marketed and Pipeline AD Products
  • Table 151: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: AD Biomarker Tests by Pathophysiology
  • Figure 2: Dynamic Changes in AD Biomarkers Over Time
  • Figure 3: 9MM, Total Prevalent Cases of AD, Ages ≥60 Years, Men and Women, N, 2013-2023
  • Figure 4: 9MM, Total Prevalent Cases of AD, by Age, Men and Women, N, 2013
  • Figure 5: 9MM, Total Prevalent Cases of AD, by Sex, Age ≥60 Years, N, 2013
  • Figure 6: 9MM, Age-Standardized Total Prevalence of AD, Age ≥60 Years, Men and Women, %, 2013
  • Figure 7: 9MM, Total Prevalent Cases of AD, by Severity, Men and Women, N, 2013
  • Figure 8: 9MM, Total Prevalent Cases of MCI, Ages ≥60 Years, Men and Women, N, 2013-2023
  • Figure 9: 9MM, Total Prevalent Cases of MCI, by Age, Men and Women, N, 2013
  • Figure 10: 9MM, Total Prevalent Cases of MCI, by Sex, Age ≥60 Years, N, 2013
  • Figure 11: 9MM, Age-Standardized Total Prevalence of MCI, Age ≥60 Years, Men and Women, %, 2013
  • Figure 12: Disease Management Timeline for AD
  • Figure 13: Active AD Clinical Trials by Drug Target, September 2014
  • Figure 14: Competitive Assessment of Late-Stage Pipeline Agents in AD, 2013-2023
  • Figure 15: Clinical and Commercial Positioning of Solanezumab
  • Figure 16: Clinical and Commercial Positioning of Gantenerumab
  • Figure 17: Clinical and Commercial Positioning of Crenezumab
  • Figure 18: Clinical and Commercial Positioning of Aducanumab
  • Figure 19: Clinical and Commercial Positioning of Flebogamma + Albutein in AD
  • Figure 20: Clinical and Commercial Positioning of Namzaric
  • Figure 21: Clinical and Commercial Positioning of MK-8931
  • Figure 22: Clinical and Commercial Positioning of AZD-3293
  • Figure 23: Clinical and Commercial Positioning of TTP-488
  • Figure 24: Clinical and Commercial Positioning of TRx-0237
  • Figure 25: Clinical and Commercial Positioning of AB-1010
  • Figure 26: Clinical and Commercial Positioning of AD-4833
  • Figure 27: Clinical and Commercial Positioning of EVP-6124
  • Figure 28: Clinical and Commercial Positioning of LuAE-58054
  • Figure 29: Clinical and Commercial Positioning of ARC-029
  • Figure 30: Company Portfolio Gap Analysis in AD, 2013-2023
  • Figure 31: Actavis SWOT Analysis in AD, 2013-2023
  • Figure 32: Lundbeck SWOT Analysis in AD, 2013-2023
  • Figure 33: Eisai SWOT Analysis in AD, 2013-2023
  • Figure 34: Pfizer SWOT Analysis in AD, 2013-2023
  • Figure 35: Novartis SWOT Analysis in AD, 2013-2023
  • Figure 36: Roche SWOT Analysis in AD, 2013-2023
  • Figure 37: Eli Lilly SWOT Analysis in AD, 2013-2023
  • Figure 38: Merck SWOT Analysis in AD, 2013-2023
  • Figure 39: AstraZeneca SWOT Analysis in AD, 2013-2023
  • Figure 40: Takeda SWOT Analysis in AD, 2013-2023
  • Figure 41: Global Sales for AD by Region, 2013-2023
  • Figure 42: Global Sales for AD by Patient Group, 2013-2023
  • Figure 43: Sales for AD in the US by Drug Class, 2013-2023
  • Figure 44: Sales for AD in France by Drug Class, 2013-2023
  • Figure 45: Sales for AD in Germany by Drug Class, 2013-2023
  • Figure 46: Sales for AD in Italy by Drug Class, 2013-2023
  • Figure 47: Sales for AD in Spain by Drug Class, 2013-2023
  • Figure 48: Sales for AD in the UK by Drug Class, 2013-2023
  • Figure 49: Sales for AD in Japan by Drug Class, 2013-2023
  • Figure 50: Sales for AD in China by Drug Class, 2013-2023
  • Figure 51: Sales for AD in India by Drug Class, 2013-2023
Back to Top